Table 2.
Summary of patient characteristics
| Characteristics | Values (%) |
|---|---|
| Assessable patients (n) | 57 |
| Age (years) | 56 (18–85) |
| Gender (male/female) | 34/23 (60%/40%) |
| Karnofsky performance score ≥70 | 57 (100%) |
| Child-Pugh score | |
| A | 56 (98.25%) |
| B | 1 (1.75%) |
| C | 0 (0%) |
| Primary tumor | |
| Colorectal cancer | 18 (31.58%) |
| Pancreatic cancer | 8 (14.04%) |
| Breast cancer | 7 (12.28%) |
| Lung cancer | 7 (12.28%) |
| Hepatocellular carcinoma | 5 (8.77%) |
| Stomach cancer | 4 (7.02%) |
| Renal cancer | 2 (3.51%) |
| Gallbladder cancer | 2 (3.51%) |
| Ovarian cancer | 1 (1.75%) |
| Esophageal cancer | 1 (1.75%) |
| Sarcoma | 1 (1.75%) |
| Olfactory neuroblastoma | 1 (1.75%) |
| LM location | |
| Right liver | 47 (58.75%) |
| Left liver | 33 (41.25%) |
| Contemporary with other site metastases | |
| Yes | 14 (24.56%) |
| No | 43 (75.44%) |
| Prior local therapy for LM | |
| Surgery | 4 (7.02%) |
| TACE | 2 (3.51%) |
| RFA plus TACE | 2 (3.51%) |
| Surgery plus RFA | 1 (1.75%) |
| None | 48 (84.21%) |
| Prior systemic therapy for LM | |
| Yes | 32 (56.14%) |
| None | 25 (43.86%) |
| Lesions per patient (n) | |
| ≤1 | 39 (68.42%) |
| >1 | 18 (31.58%) |
| Time interval between the first liver metastasis and CyberKnife® treatment (months) | 2.2 (0.3–33.5) |
Notes: Data are presented as the median and ranges; favorable group (primary tumors originating from the colon, breast, or stomach, as well as sarcomas); unfavorable group (primary tumors originating from the pancreas, lung, ovary, gallbladder, uterus, hepatocellular carcinoma, as well as olfactory neuroblastoma).
Abbreviations: LM, liver metastases; RFA, radiofrequency ablation; TACE, trans-catheter arterial chemoembolization.